DanBAN and DTU Science Park are joining forces in a new initiative between DanBAN’s professional network, “HealthTech & LifeScience,” and DTU Science Park’s MedTech Growth program, with a focus on strengthening the investment readiness of Danish medtech startups and creating closer dialogue between founders and investors.
Medtech companies operate in a field with long regulatory processes and complex market conditions. At the same time, the market for early-stage investments has become more selective. Both factors increase the need for strong preparation and a clear investment case.
Therefore, DanBAN HealthTech & LifeScience and DTU Science Park MedTech Growth are joining forces on a structured capital readiness program.
The initiative involves more than 25 investors from DanBAN’s professional network. A smaller group of professional business angels will be connected to each startup and will jointly work in a targeted way with market understanding, milestones, financial plans, and valuation. The program concludes with a pitch event for a broader group of investors.
The collaboration was launched with a kickoff session where 17 business angels met the startups in a café-style format, followed by a panel discussion with Gitte Stausholm, Business Angel, Mikkel Kristiansen, CEO of VentriJect, and Katrine Riisberg, Investment Associate at Delphinus Venture Capital, moderated by Jan Rosenbom from DTU Science Park, sharing perspectives on what drives investment decisions.
The purpose is to strengthen the quality of investment cases and create a more qualified and transparent dialogue between founders and investors.
With this collaboration, we contribute concrete investor experience and structured sparring, enabling companies to stand stronger in their capital raising and bring their solutions all the way to market.
Christoffer Melchior
Business angel and active member of DanBAN’s HealthTech & LifeScience network.
The collaboration is anchored in MedTech Growth, DTU Science Park’s accelerator program, which annually works with 10–14 medtech startups and prepares them for market entry and capital raising.
I am pleased that we are now launching this coaching program in collaboration with DanBAN’s HealthTech & LifeScience network. MedTech companies face extensive regulatory requirements, demands for clinical documentation, and long development cycles, which often make external financing necessary. When DanBAN’s investors share how they assess risk, potential, and long-term value creation, it gives our startups a more realistic and nuanced understanding of what the journey entails. We greatly appreciate their willingness to engage closely in MedTech Growth and their contribution of both time and experience to this collaboration.
With this initiative, DanBAN and DTU Science Park take a joint step towards a more coherent and professional capital environment for Danish life science companies.
The ambition is to ensure that more innovative solutions reach patients and the healthcare system!
